Personalising myasthenia gravis medicine: from “onefits- all” to patient-specific immunosuppression
Lombady partners:
- Renato Mantegazza Fondazione IRCCS Istituto Neurologico Carlo Besta
- Fabio Stella Università degli Studi Milano-Bicocca
|
Pathology of interest: |
Myasthenia Gravis (MG) |
|
Area of research: |
Autoimmune diseases |
|
Start date: |
1 March 2023 |
|
End date: |
28 February 2026 |
|
Funding: |
€ 500.000,00 |
|
Project partners: |
Fondazione IRCCS Istituto Neurologico Carlo Besta, Italy
Centre of Research in Myology, INSERM – Sorbonne University, France Hadassah University Hospital, Israel University of Milan-Bicocca, Italy University of Copenhagen, Denmark |
Myasthenia Gravis (MG) is a prototypic autoimmune disease causing muscle weakness and fatigability, frequently treated with lifelong immunosuppressive therapy (IST). Clinical heterogeneity, unpredictable disease course, treatment refractoriness in a proportion (10-15%) of patients, IST-related adverse events, and inter-individual variation in response to both conventional IS and emerging biological drugs highlight the need to adopt more effective, preventive and safe personalised medicine (PM) strategies, still lacking in MG. The MG-PerMed project will combine pre-clinical, clinical, artificial intelligence (AI), telemedicine and bioethics research to promote adoption of PM in MG clinical practice. Integration of biomarker with real-world clinical data from three MG populations (Italian, French and Israeli) via AI will allow the development of a clinical decision support tool (MG-CDST), whose effectiveness in guiding the choice of the best patientcentred treatment programme will be proven in an exploratory clinical study. Our findings will set the basis for a shift from the current “one-fits-all” treatment flow-chart to personalised care in MG, thus promising to significantly improve therapeutic success and MG patients’ quality of life.